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ABSTRACT 8 
A study that combines microneedles and sonophoresis pre-treatment was explored to determine 9 
their combined effects on percutaneous delivery of lidocaine from a polymeric hydrogel formulation. 10 
Varying ratios of carboxymethylcellulose and gelatine (NaCMC:gel range are 1:1.60-1:2.66) loaded 11 
with lidocaine were prepared and characterised for zeta potential and particle size. Additionally, 12 
variations in the formulation drying techniques were explored during the formulation stage. Ex-vivo 13 
permeation studies using Franz diffusion cells measured lidocaine permeation through porcine skin 14 
after pre-treatment with stainless steel microneedles and 20 kHz sonophoresis for 5 and 10 minute 15 
durations. A stable formulation was related to a lower gelatine mass ratio because of smaller mean 16 
particle sizes and high zeta potential. Lidocaine permeability in skin revealed some increases in 17 
permeability from combined microneedle and ultrasound pre-treatment studies. Furthermore, up to 18 
4.8 fold increase in the combined application was observed compared with separate pre-treatments 19 
after 30 minutes. Sonophoresis pre-treatment alone showed insignificant enhancement in lidocaine 20 
permeation during the initial 2 hours period. Microneedle application increased permeability at a time 21 
of 0.5 h for up to ~17 fold with an average up to 4 fold. The time required to reach therapeutic levels 22 
of lidocaine was decreased to less than 7 minutes. Overall, the attempted approach promises to be a 23 
viable alternative to conventional lidocaine delivery methods involving painful injections by 24 
hypodermic needles. The mass transfer effects were fairly enhanced and the lowest amount of 25 
lidocaine in skin was 99.7% of the delivered amount at a time of 3 hours for lidocaine NaCMC/GEL 26 
1:2.66 after low frequency sonophoresis (LFS) and microneedle treatment.  27 
Keywords Carboxymethylcellulose, gelatine, microneedles, sonophoresis, lidocaine, percutaneous  28 
 29 
Abbreviations: Degree of substitution (D.S.), sodium carboxymethylcellulose (NaCMC), gelatine 30 
(gel) 31 
1. Introduction 32 
This paper is concerned with the delivery of lidocaine, a common anaesthetic, from a lidocaine 33 
carboxymethylcellulose with gel co-polymer hydrogel formulation such as discussed recently by 34 
Nayak et al. (2013). An ideal anaesthetic can be described as one that provides rapid, prolonged 35 
and effective localised anaesthesia via a mechanism of blocking sensory nerve fibres in the 36 
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periphery that induces no pain and causes no adverse local tissue reaction (Rudin, 2013; Richards 37 
and McMahon, 2013; Milewski and Stinchcomb, 2011). Lidocaine hydrochloride is a water soluble 38 
weak acid, fully ionised at pH 5.0 and administered into the plasma rich layer under the skin surface 39 
(González-Rodríguez et al., 2013; Igaki et al., 2013). However, this administration is conventionally 40 
performed via hypodermic needles as a low cost and fast acting method (Kim et al., 2012; Hedge et 41 
al., 2011). This is known to cause significant pains (Scarfone et al., 1998). Alternatives, such as 42 
eutectic mixture of local anaesthetics (EMLA), a topical form to administer lidocaine, require at least 43 
an hour of application to achieve effective analgesia, thus limiting its use especially in emergency 44 
situations (Nayak and Das, 2013). Therefore, there are important rationales for the pursuits of 45 
alternative lidocaine administration (Nayak et al., 2013; Nayak and Das, 2013). This can be 46 
evidenced in the European paediatric drug legislation which backs innovative approaches to 47 
develop ‘easy to administer’ and ‘minimally invasive’ drug delivery methods (Shah et al., 2011). The 48 
alternative rationales for lidocaine delivery include the need for increased safety amongst the 49 
patients and healthcare providers, increased compliance with those who possess a fear of needles, 50 
reduced discomfort and pain especially in the case of applying anaesthetics as well as improved 51 
ease of delivery (Gill and Prausnitz, 2007; Giudice and Campbell, 2006; Li et al., 2010). Oral 52 
administration can overcome many of the disadvantages associated with direct injection of drugs 53 
(Bal et al., 2010). However, one constraint is low bioavailability of some drugs which limits the 54 
effectiveness as therapeutic targets (Shipton, 2012; Benet et al., 1996; De Boer et al., 1979; Huet 55 
and Lelorier, 1980). Lidocaine’s oral bioavailability is approximately reduced by 65 - 96%, mainly by 56 
hepatic enzymes (Fasinu et al., 2011; Fen-Lin et al., 1993). In principle, innovative percutaneous 57 
delivery method could be used to overcome the barriers associated with direct injection and oral 58 
administration of drugs (Polat et al., 2011) such as lidocaine. The rate of passive diffusion (PD) of 59 
drugs by percutaneous delivery depends on the molecular structure, size and hydrophobicity in 60 
conjunction with the drug concentration gradients. However, many studies have used combinations 61 
of PD and non-invasive techniques with varying success, e.g., microneedles and ultrasound (Han 62 
and Das, 2013; Chen et al., 2010). This is the topic of this paper and it is discussed in more detail 63 
below. 64 
 65 
Microneedles are needle-like structures of the size order of microns commonly arranged in a matrix 66 
(Gill and Prausnitz, 2007; Zhang et al., 2014; Olatunji et al., 2014). The geometry of microneedle 67 
influences its ability to pierce the skin but importantly, it can be designed to control/optimise the rate 68 
of drug delivery. The lidocaine NaCMC/GEL hydrogels pseudoplasticity permits the viscous 69 
formulation in allowing seepage into microneedle cavities to bypass the stratum corneum skin layer 70 
compared with passive diffusion (Nayak et al., 2013). Research has shown that a significant 71 
increase in skin permeability can be achieved when optimised microneedle arrays are used where 72 
the important factors include microneedle length, number of microneedles, the length and width 73 
aspect ratio and surface area of the microneedle patch (Al-Qallaf and Das, 2008; Al-Qallaf and Das, 74 
2009; Olatunji et al., 2012; Olatunji et al., 2013; Guo et al., 2013). It has been suggested that 75 
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microneedles can be adapted to aid lidocaine delivery yielding many fold increase in delivery rate 76 
(Kwon, 2004; Li et al., 2008; Wilson et al., 2008; Kochhar et al., 2013; Ito et al., 2013; Zhang et al., 77 
2012; Zhang et al., 2012; Nayak et al., 2013).  78 
 79 
In a recent review paper, Nayak and Das (2013) have discussed the possibility of delivering 80 
lidocaine using biodegradable micro-needles. In exploring alternative applications of microneedles, 81 
a number of other studies have successfully delivered numerous active molecules using 82 
microneedles, e.g., hepatitis B vaccine (Guo et al., 2013), Solaraze® gel in extending pore opening 83 
(Ghosh et al., 2013b) and naltrexone co-drug with diclofenac drug (Banks et al., 2013). In another 84 
recent study, it has been shown that microneedles can be combined with ultrasound for increasing 85 
the delivery rate of a large macromolecular drug (Han and Das, 2013). These studies have further 86 
raised the hypothesis that microneedles and ultrasound combination could be used for greater 87 
epidermal lidocaine delivery in order to determine the significance of optimum sonophoretic power 88 
related the effects on lidocaine permeation.  89 
 90 
In this context, it is important to state the classification of sonophoresis which is generally based on 91 
the frequency of ultrasound. The low frequency sonophoresis (LFS) is defined to be within the range 92 
of 20-100kHz and the high frequency sonophoresis (HFS) is usually for above 0.7MHz (Polat et al., 93 
2011). The mechanism by which enhanced permeability is achieved via ultrasound can be linked to 94 
a number of physical phenomena including thermal effects, formation of cavitation, mechanical 95 
effects and convective localised fluid velocities in skin (Lavon and Kost, 2004). However, in the 96 
ultrasound pretreatment experiment, it is generally accepted that inertial cavitation is the largest 97 
contributor to the enhancement in skin permeability. It is more so with LFS as shown by Merino et al 98 
(2003) due to larger bubble size at low frequency range. Inertial cavitation occurs due to pressure 99 
variations induced by ultrasound, resulting in rapid growth and collapse of bubbles formed in the 100 
coupling medium. The collapsing of the aforementioned bubbles near skin surface will cause micro-101 
jets due to asymmetrically release of energy. These micro-jets have been confirmed as the main 102 
contributors to the permeability increment (Wolloch and Kost, 2010). The effects of ultrasound have 103 
been studied for the enhancement of transdermal lidocaine administration with significant 104 
enhancement demonstrated with both pulsed and continuous output mode of LFS (Ebrahimi et al., 105 
2012). However, as far as we are aware of, these techniques are yet to be combined and studied for 106 
permeability enhancement levels, particularly for lidocaine. 107 
 108 
The potential for adapting microneedles for lidocaine delivery via hydrogel microparticles has been 109 
discussed previously with the conclusion that there is significant commercial potential for lidocaine 110 
microneedle products (Zhang et al., 2012; Nayak et al., 2013). Polymeric hydrogel microparticles 111 
are good for the purpose of controlling spreading (i.e., controllable spreading radius, droplet height 112 
and contact angle) of the drug formulation over skin (Nayak et al., 2013). A hydrogel drug vehicle 113 
comprises the electrostatic polyionic interaction of a branched structural polymer with a relatively 114 
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linear polymer in the formation of a cross-linked matrix to encapsulate Lidocaine molecules (Zhao et 115 
al., 2006; Lastumäki et al., 2003).  116 
 117 
In this particular study, the drug vehicle for lidocaine encapsulation is polyanionic, carbohydrate 118 
based NaCMC crosslinked with polycationic, protein based gel in forming a hydrogel (Nayak et al., 119 
2013). Previously lidocaine formulation bypassing the stratum corneum (SC) epidermal layer was 120 
outlined, the viscoelastic properties in adapting a NaCMC/gel network hydrogel prevents slippage of 121 
the drug formulation when applied to the skin and the possibility of non-convective flow through the 122 
opened cavities of the skin from microneedle treatment (Milewski and Stinchcomb, 2011; Ghosh et 123 
al., 2013a). To try and exploit this potential the main aim of the study is to combine the techniques in 124 
microneedle array and ultrasound technology as a pre-treatment to meet the definition of an ideal 125 
anaesthetic delivery method. Furthermore, this study will focus on using solid microneedles utilising 126 
the ‘poke and patch’ technique. The main advantage of this approach is the technical simplicity 127 
required for reproduction of the required micro-needles leading to reduction of cost. The other major 128 
advantage is that an extended release is possible using this approach. A carbohydrate based 129 
visceral hydrogel formulation was prepared as a model anaesthetic as this provides flexible 130 
properties and ability to encapsulate considerable amounts of liquid drug, lidocaine in this instance 131 
(Milewski and Stinchcomb, 2011), as discussed in the following section. Furthermore, the spreading 132 
behaviour of the prepared formulation was studied  and compared with the spreading behaviour 133 
lidocaine solution as a Newtonian liquid. Unlike numerous studies performed using synthetic 134 
substrates, this study implements porcine skin as a lipophilic substrate as was attempted by Chow 135 
et al. (2008). 136 
 137 
2. Materials and methods 138 
NaCMC and gel emulsion was crosslinked to form hydrogels with encapsulated lidocaine in batch 139 
scale production. This formulation setup is highly beneficial because of fairly efficient preparation 140 
times in achieving a finished drug formulation and low heat treatment in adaptation of green 141 
chemistry.  142 
 143 
2.1 Materials and equipments 144 
Sodium carboxymethylcellulose (D.S. 0.9; M.W. 250kD), sorbitan mono-oleate (SPAN 80), 145 
glutaraldehyde 50% w/w, paraffin liquid (density range: 0.827-0.89 g/ml), lidocaine hydrochloride 146 
(M.W. 288.81 g/mol), methylene blue (50 % v/v) and porcine gelatine (type A) were purchased from 147 
Sigma Aldrich Ltd (Dorset, UK). Analytical grade acetic acid, high performance liquid 148 
chromatography (HPLC) grade acetonitrile and n-hexane (95% w/w) were purchased from Fisher 149 
Scientific UK (Loughborough, UK). A Gemini-NX column (C18) of particle size 3 µm was purchased 150 
from Phenomenex (Cheshire, UK) for HPLC instrumentation. Amputated porcine ears (age of pig: 5-151 
6 months) were purchased from a local butcher and dissected into 20 mm x 20 mm squares before 152 
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storage at -20 ± 1ºC. Also 10 mm x 10 mm squares of same porcine skin were dissected as a 153 
substrate for droplet spreading. Microneedle patch (stainless steel, flat arrow head geometry and 154 
1100µm length) was purchased from nanoBioSciences (Sunnyvale, CA, USA). Branson Digital 155 
Sonifier 450 (Danbury, USA) was chosen as the ultrasound output system. This ultrasound system 156 
includes an auto-calibrated transducer and a digital output controller. The frequency of the 157 
ultrasound is fixed at 20 kHz but the output powers are adjustable between 4 and 400 W. The 158 
equipment for droplet spreading studies were AVT Pike F-032 high performance camera (Allied 159 
Vision Technologies UK), Camera i-speed LT high speed video (Olympus, UK), 160 
2.2 Formulation of lidocaine NaCMC:gel hydrogel 161 
Paraffin oil (100 ml) was sheared continuously for up to 400 rpm in a stirred vessel bought from IKA 162 
(Staufen, Germany). Span 80 (0.5% w/w) was dispensed in ambient conditions. To this NaCMC 163 
(1.24 % w/w) in ultrapure water was added dropwise, and depending on the polymeric ratio (c % 164 
w/w), gel in ultrapure water was also added dropwise at 35-40ºC (Table 1). A subsequent pH 165 
reduction of the solution to pH 4.0 was performed by the addition of acetic acid (~3% w/w). While 166 
shearing at 400 rpm, lidocaine HCl (2.44 % w/w) was added dropwise in ultrapure water at 20°C into 167 
the polymer mixture. The polymeric mixture was then cooled to 5-10ºC for 30 minutes to initially 168 
harden the microparticles. Glutaraldehyde (0.11 % w/w) was added to the emulsion as a cross linker. 169 
Upon returning to 20°C temperature the hydrogel mixture was sheared for 2 hours at approximately 170 
1000 rpm to ensure thorough mixing. The lidocaine NaCMC/gel formulation was then left to stand 171 
until a distinct w/o boundary was observed after which this formulation was left overnight at 1-5ºC. 172 
Excess paraffin liquid was removed via n-hexane separation shaking (50 % v/v); top organic layer 173 
was discarded before placing the hydrogel formulation in a vacuum oven (Technico, Fistreem 174 
International Ltd, Loughborough, UK) under full vacuum and a temperature of 20ºC for 8 hours. 175 
Following this, the formulation was washed with deionised (DI) water and filtered using commercial 176 
filter papers with pore size 6 µm (Whatman, Ltd, Oxon, UK) for removal of unbound lidocaine before 177 
further characterisation. In the case of F5 residual paraffin and n-hexane were removed by rotary 178 
evaporation (Heidolph Instruments, Essex, UK). Similarly, the formulation was washed with DI water 179 
and filtered as previously outlined. 180 
 181 
2.3 Zeta potential of lidocaine NaCMC:gel hydrogel 182 
The zeta potential was measured using a Zetasizer (3000 HSa, Malvern Instruments, 183 
Worcestershire, UK). Lidocaine NaCMC/gel (2.0 ± 0.5 g/ml) in DI water was injected into the sample 184 
port, temperature maintained at 25.0°C and the results were obtained in triplicate. The zeta-potential 185 
(ζ) was measured in terms of electrophoretic mobility (µ) via an optical technique, and ζ (mV) (Park 186 
et al., 2005) of the diluted hydrogel was computed from the Smoluchowski equation (2) where µ is 187 
referenced with latex (m2 v-1 s-1), ƞ is the DI volume viscosity (m2s-1), εo and εr are the permittivity in 188 
a vacuum and relative permittivity of DI water as medium respectively (Sze et al, 2003). 189 
Table 1 
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𝜁 =  4𝜋𝜇𝜂(𝜀𝑟𝜀𝑜)                                                  (2) 190 
 191 
2.4 Viscometric analysis of lidocaine NaCMC:gel hydrogel 192 
A well-mixed sample volume (25 ml) of lidocaine NaCMC/gel hydrogel sample was determined for 193 
variations to viscoelastic properties at standard temperatures of 20°C. An inducing shear rotating 194 
viscometer (Viscotester VT550, Haake, Germany) with rotor and cup (NV1) assemblies and a 195 
constant ravine of 0.35 mm, in between the assembly was adapted in viscometric analysis. More 196 
details on this aspect of our work are presented by Nayak et al. (2013). 197 
 198 
2.5 Optical micrographs of lidocaine NaCMC:gel hydrogel 199 
Micrographs were obtained using an optical microscope (BX 43, Olympus, Southend-on-sea, UK) 200 
and a camera attachment captured coloured still images (Retiga-2000R, QImaging, British 201 
Columbia, Canada). Micrographs were pictured in triplicate for each formulation. An image 202 
processing software (ImageJ) was adapted in pixel measurement via graticule calibration to 203 
interpret particle size diameters from a random selection of 50 microparticles per image. ImageJ is a 204 
Java-based open source image processing and analysis program developed at the National Institute 205 
of Health (NIH), USA. 206 
 207 
2.6 Controlled release of lidocaine from NaCMC/gel hydrogel 208 
Lidocaine NaCMC/gel hydrogel (0.1 ± 0.05 g) was placed in an amber vial and 25.0 ml of DI water 209 
was dispensed before the sample was placed in a pre-heated thermo-stat bath at 37.0 ± 0.5°C 210 
(Grant Instruments, Cambridge, UK). Subsequently 1 ± 0.0005 ml of heated sample removed by 211 
autopipette (Eppendorf, Stevenage, UK), filtered using Nylon membranes (Posidyne, 0.1 µm) and 212 
analysed for lidocaine content using HPLC instrumentation. The results were measured in triplicate 213 
and the standard deviation from sample mean was taken. 214 
 215 
2.7 Ex vivo skin permeation study of lidocaine NaCMC/gel hydrogel 216 
Jacketed Franz diffusion cells (FDC) (Logan Instruments, New Jersey, USA) were used as 217 
previously annotated for determining the ex vivo drug permeation rate through porcine skin (Nayak 218 
et al., 2013). Porcine ear skin was used in this analysis because of the histological similarity with 219 
human skin. Dissected square skin sections (20 x 20 mm) were defrosted at 25°C for a maximum 220 
time of 1 hour before the commencement of this study. The FDC receptor chamber (5.0 ml) was 221 
filled with deionised water and constantly stirred using a magnetic flea. The FDC receptor volume 222 
was constantly maintained at 37 ± 1ºC through a water jacket. A square section of full thickness skin 223 
(subcutaneous fat and connective tissue removed) was placed on the top of the aperture surface of 224 
diffusion cell with a diffusion area of 1.33cm2. The average skin thickness was recorded in the range 225 
of 760-787µm (± 25 µm). The continuous viscoelastic properties of skin are unlikely to allow for 226 
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microneedles to penetrate beyond 200 µm when considering 1500 µm needle length rollers 227 
penetrating a depth of 150µm (Roxhed et al., 2007; Badran et al., 2009). The lidocaine NaCMC:gel 228 
hydrogel (0.10 ± 0.03g) was placed on to the skin’s donor compartment, the split second timer 229 
initiated and then the skin was securely clamped with a donor lid. A fixed 1.5ml receptor volume was 230 
syringe removed periodically from the receptor chamber and replaced with 1.5ml of deionised water. 231 
Following this the samples were analysed for free lidocaine using HPLC instrument (Agilent 1100 232 
series, Hewlett Packard, U.S.). Similar FDC method was used for all drug release experiments 233 
concerning passive diffusion, microneedles only pre-treatment, LFS only pre-treatment, 234 
microneedles and LFS pre-treatment. Microneedles were carefully applied to the skin ensuring 235 
penetration and held in place using a constant pressure device comprising of a pneumatic piston 236 
(0.05MPa) for 3 or 5 minutes. LFS was supplied using a probe set to 20 kHz frequency for 5-10 237 
minutes. Continuous application of ultrasound was implemented due to no significant difference 238 
being observed during pre-treatment applications (Herwadkar et al., 2012). The inter-coupling 239 
distance between the skin and probe was set to 2mm with coupling medium of deionised water. A 240 
minimum lidocaine concentration of 1.5 μg/ml was deduced from literature as the permissible 241 
effective drug therapeutic value in plasma (Schulz et al., 2012; Grossman et al., 1969).  242 
 243 
2.8 Spreading of lidocaine NaCMC;gel 1:2.33 across porcine skin 244 
The setup for measurement of spreading radius, droplet height and apparent contact angle of 245 
droplet was similar to Chao et al (2014). A square section of porcine skin (10 mm x 10 mm) was 246 
placed flat in a closed sample box. A sample droplet (3.0 ± 0.5µl) was dispensed on the porcine 247 
skin, camera frame rate capture of 1.85 frames per second (fps) was maintained and the results 248 
recorded. Results were obtained in duplicate for the optimum particle size controlled formulation and 249 
compared with a duplicate set of lidocaine solution of the same lidocaine loading weight (2.44 % wt). 250 
 251 
2.9 Histological study  252 
The determination of microneedle insertion depth into skin by post microneedle treatment of skin 253 
was adapted from Cheung et al (2014). First, the skin sample is pretreated using 1100 µm 254 
microneedle patch for 5 min. Then, the porcine skin sample is stained using methylene blue (50% 255 
v/v) and merged into embedding compound (Bright Cryo-m-Bed, Huntingdon, UK) which is filled in a 256 
cuboid mould. The whole sample is then put inside the microtome (Bright Cryostat 5030, 257 
Huntingdon, UK) to solidify. The frozen sample is cut into 15 µm slices and analysed under the 258 
microscope for the histology. 259 
 260 
3. Results and discussions 261 
3.1. Lidocaine NaCMC/gel hydrogel microparticle size diameters and morphology 262 
Lidocaine encapsulated hydrogel microspheres based on NaCMC and gelatine were prepared using 263 
glutaraldehyde in transforming emulsion droplets to defined microparticles. As the mechanisms for 264 
ionic interactions in forming spherical microparticles are known (Gupta et al., 2000; Berger et al., 265 
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2004), it is not discussed in detail in this paper. The morphological observations of lidocaine 266 
NaCMC:GEL microparticles are spherical, well-formed and slightly agglomerated for a significant 267 
number of them (Fig. 1a, 1b). Mean particle size diameters (Table 1) in the formulation ranged from 268 
5.89-14.60µm depending on the formulation with an increase in mean particle size observed with an 269 
increased gelatine ratio. This is the likelihood of increased gelatine component of the hydrogel, 270 
producing larger droplets during the w/o emulsification and subsequent hardening after the addition 271 
of glutaraldehyde. The rotary evaporation method yielded significantly larger particle sizes in 272 
comparison to vacuum drying. Interestingly, a positively skewed particle size distribution was 273 
observed for all lidocaine hydrogel formulations (Fig. 2). 274 
 275 
 276 
 277 
3.2. Dispersion of lidocaine NaCMC/gel hydrogel microparticles 278 
Zeta potential studies in lidocaine NaCMC/gel hydrogels demonstrated a stable and fairly dispersed 279 
microparticulate system. The results (Fig. 3) expressed a trend of decreasing stability with an 280 
increase in the gelatine ratio, which in theory should impact a greater level of microparticle 281 
agglomeration thus likely affecting the permeability through skin. The pH of all formulations was kept 282 
constant and therefore it should not have affected the zeta potential although the slight decline of ζ-283 
potential in the positive direction is linked to the increase in gelatine ratio caused by gelatine in 284 
conjunction to lidocaine possessing a positively charged tertiary amide group at pH 4.0 and thus 285 
contributing to the increasing negative surface charge. The anionic polymer, sodium carboxymethyl 286 
cellulose has a ζ-potential value of -30mV (Ducel et al., 2004) and electric charge neutralisation did 287 
not occur or was not significantly induced by gelatine or lidocaine, so the overall lidocaine 288 
NaCMC:gel hydrogel charge was greater than -30mV. Nevertheless, reduced agglomeration is the 289 
result of a medium pKa, higher dielectric constants in comparison to a polymeric hydrogel 290 
components converging to significantly low overall ζ-potential range of -35 to -40mV and effect of 291 
electrostatic particle repulsion (Xu et al., 2007). 292 
 293 
 294 
 295 
3.3. Viscoelasticity of lidocaine NaCMC/gel hydrogel 296 
Viscosity determination (Fig. 4) revealed a lenient pseudoplastic nature for the formulation with 297 
lidocaine NaCMC/gel hydrogel with good correlative best fit curves observed for individual set of 298 
data points (R2 > 0.93). The dynamic viscosity plots showed similar mild pseudoplastic behaviour 299 
between the formulations with lidocaine NaCMC/gel 1:2.66 hydrogel being marginally higher when 300 
considering the upper viscosity range of 0.5 to 0.6 Pa.s at a starting shear of 25 s-1 and then more 301 
defined shear thinning behaviour observed above 100 s-1. Lidocaine with sodium 302 
carboxymethylcellulose as a polyanionic vehicle alone will not be sufficient in enhancing 303 
Fig. 1 Fig. 2 
Fig. 3 
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pseudoplastic properties and a recent study has shown that the profile of a dynamic viscosity plot is 304 
Newtonian (Alaie, 2013). 305 
 306 
 307 
3.4 Control of lidocaine NaCMC:gel 1:2.33 spreading on porcine skin.  308 
The spreading radius and height of lidocaine NaCMC/gel 1:2.33 outline significant control on its 309 
spreading behaviour compared with lidocaine solution of the same mass loading (Fig. 5a and 5b). 310 
The beginning of the plateau effect is observed after 10 seconds and therefore, there is expected to 311 
be a localisation effect on the skin surface (Fig. 5a and 5b). The apparent contact angles of 312 
lidocaine NaCMC/gel 1:2.33 droplets are considerably higher than the lidocaine solution contact 313 
angle droplets, near to the skin impact time of 0 seconds (Fig 5b). Apparent contact angle stability is 314 
noticed after 40 seconds (Fig. 5c). Our results also show that the lidocaine solution is a Newtonian 315 
liquid that can spread a much faster than lidocaine NaCMC/gel microparticles. 316 
 317 
 318 
3.5. The percentage release of lidocaine from controlled release of lidocaine. 319 
All four lidocaine NaCMC/gel hydrogels outline rapid release of lidocaine directly in DI water during 320 
the first 1 hour with steady state conditions observed in the next three hours (Fig. 6a).  A 0.3 fold 321 
decrease in cumulative release is observed in the first hour when comparing lidocaine NaCMC/gel 322 
1:1.6 with lidocaine NaCMC/gel 1:2.66 as the highest releasing outline. Also, a 0.1 fold decrease in 323 
cumulative release was observed in the next three hours when comparing lidocaine NaCMC/gel 324 
1:1.6 with lidocaine NaCMC/gel 1:2.66. This shows that the variation between hydrogel ratios is not 325 
significantly large as permeation release profiles explained in the following sections. The percentage 326 
release of lidocaine from NaCMC/gel hydrogels were determined by the following equation 1: 327 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 = 𝑀𝑠−𝑀𝑡
𝑀𝑠
 𝑥 100                                     1) 328 
Where Ms is the maximum mean cumulative steady state concentration of drug and Mt is the mean 329 
cumulative concentration of lidocaine taken specifically at release time. The highest amount of 330 
Lidocaine released was from NaCMC/gel 1:1.6 hydrogel in which 32.3% was detected in the DI 331 
water media in one hour (Fig. 6b). This is because the smaller particles sizes of Lidocaine 332 
NaCMC/gel 1:1.6 ratio allow for a greater surface area and encapsulated lidocaine thus rapidly 333 
dissolves in DI water. The lidocaine NaCMC/gel 1:2.66 ratio comprises larger microparticles and 334 
therefore a smaller surface area is exposed for DI water dissolution so the percentage of lidocaine 335 
released was 17.4% in one hour. Significantly less amounts of lidocaine is released for all 336 
NaCMC/gel hydrogel formulations after 1 hour reflecting the steady state conditions of the hydrogel 337 
as the DI water media becomes a saturated solution.    338 
Fig. 4 
Fig. 5 
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 340 
3.6 Histological analysis on the microneedles  341 
The microneedles that are employed in the histological experiment are 1100 µm in length. The 342 
purpose of the histological experiment is to determine the insertion depth of this microneedle patch 343 
under thumb pressure for which post-microneedle treated skin is micrograph imaged (Fig. 7). 344 
According to Fig.7, the insertion depth is between 300 µm and 400 µm which are much lower than 345 
the real length of microneedles. This is caused by several reasons, such as the viscoelastic 346 
properties of the skin, the geometry of the microneedles and the insertion force. This reduced 347 
insertion depth can further affect the permeation results. 348 
 349 
 350 
3.7 Passive diffusion of lidocaine NaCMC/gel hydrogel 351 
Skin passive diffusion experiments were carried out in order to provide a control from which any pre-352 
treatment enhancement results can be compared and contrasted. The lowest polymeric 353 
microparticle ratio 1:1.6 of lidocaine (Fig. 8a) outlines the most desirable cumulative permeation for 354 
lidocaine in crossing the minimum threshold therapeutic level after 0.57 hours. This is the shortest 355 
lag time for reaching the pain receptors for lidocaine in the deep dermis region rich in watery plasma 356 
and nerves. The hydrogel microparticle chemistry is a combination of significantly high negative zeta 357 
potential and smaller mean particle size contributing to an increased permeation. All lidocaine 358 
NaCMC/gel ratio hydrogels have demonstrated a very low initial permeation at a maximum of 359 
0.3µg/ml reached in 0.5 hours. This is the normal lag time because of a longer path length for 360 
microparticle permeation when considering the topmost SC layer surface area bigger than the 361 
accessible VE layer microcavities. However, lidocaine NaCMC/gel 1:2.0 and lidocaine NaCMC/gel 362 
1:2.66 hydrogels are the next two favourables after the most desirable formulation containing a 363 
polymeric mass ratio 1:1.6 for bypassing the minimum therapeutic threshold at a shorter time 364 
interval. Initially, lidocaine is diffusing through the fresh skin because of microparticulate disruption 365 
to the hydrogel formula caused by natural skin moisture hence the low initial concentration rates 366 
proceeding upto 0.5 hours. Due to the requirements of lidocaine as an fast acting anaesthetic the 367 
current results confirm enhancement of permeation is required if minimum therapeutic threshold of 368 
lidocaine (1.5µg/ml) are to be reached within a suitable time frame for this technique to be of 369 
practical use. The lag time to cross a minimum therapeutic level is slightly greater than 1 hour in 370 
lidocaine NaCMC/gel 1:2.33 hydrogel and just over 2 hours for lidocaine NaCMC/gel 1:2.66 371 
hydrogel, rotary evaporation method with respect to passive diffusion alone which is considerably a 372 
long, unreasonable waiting time for a promising polymeric hydrogel ointment drug. The cumulative 373 
lidocaine thresholds tend to stabilise post 4 hours, where equilibrium is reached and no more drug is 374 
Fig. 6 
Fig. 7 
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released into the concentrated dermal region. This means that the lidocaine hydrogel ointment can 375 
be washed off the skin. Lidocaine NaCMC/gel hydrogel was compared with lidocaine solution 376 
permeation from literature (Sekkat et al., 2004). Prior to this passive diffusion comparison with 377 
lidocaine solution passive diffusion, the permeation units of µg/ml were converted into µg/cm2 by the 378 
product of the known receptor volume followed by the quotient of the adjustment factor value of 2.36 379 
(3.14 cm2/ 1.33 cm2) due to the increase in FDC diffusion area when comparing a similar study 380 
using a smaller aperture diameter (Sekkat et al., 2004). The current lidocaine NaCMC/gel 1:1.6 381 
hydrogel crosses the minimum therapeutic threshold by 1.8 fold than lidocaine solution on similar 382 
full thickness skin despite lidocaine solution permeating initially at 1.4 fold faster before a half an 383 
hour time frame and not anywhere near the minimum therapeutic threshold (Sekkat, 2004). 384 
Lidocaine NaCMC/gel 1:2.66 and lidocaine NaCMC/gel 1:2.66 hydrogel formulated by rotary 385 
evaporation were chosen to be studied for further enhancement via pre-treatment. The factor of 386 
permeation enhancement can be deduced when making this comparison. 387 
 388 
 389 
 390 
3.8 Ultrasound only pre-treatment of lidocaine NaCMC/gel ratio 1:2.66 hydrogel 391 
To observe the effect of power and application time of LFS has on permeation, LFS was applied 392 
continuously with varying power and exposure time as shown in Fig. 8b. Theoretically, the exposure 393 
of LFS should form inertial cavities in the coupling medium and develop micro-jets toward the skin 394 
surface to aid permeation. However, lidocaine transport through the skin saw no significant 395 
enhancement up to 2 hours after which a significant enhancement, especially power induction, 18W 396 
at 10 mins for lidocaine NaCMC/gel 1:2.66 (T-test P<0.026) outlined a greater permeation profile. 397 
The results conclude that an increase in power has a greater enhancement effect compared to an 398 
increase in LFS exposure time; however, no significant increase in lidocaine transport through the 399 
skin was observed during the initial stages after varying respective power induction and time 400 
durations while maintaining constant NaCMC/gel ratios of lidocaine hydrogel drug application. It is 401 
predicted that a higher LFS power level would further increase diffusion; however, the risk of 402 
thermal effects would be too high for this to be of practical use. 403 
3.9 Microneedle pre-treatment of lidocaine NaCMC/gel ratio 1:2.66 hydrogel 404 
PD permeation (Fig. 8d) and microneedle assisted (MN) permeation (Fig. 8c) with a post application 405 
time limit of 3 and 5 minutes concurrently were compared altogether. Microneedle only pre-406 
treatment of lidocaine NaCMC/gel 1:2.66 hydrogel generated a substantial increase in lidocaine 407 
permeation for both the 3 and 5 minute post MN duration (Fig. 8c). A statistically significant 408 
difference (P<0.04) was observed for MN application duration. Initial (t=0.5h) permeation for the 3 409 
and 5 minute patch duration resulted in increases of 9 and 17 fold respectively. An average 3 fold 410 
increase in permeation was observed for the 3 minute microneedle application and comparatively 411 
an increase by 4 fold for a 5 minute microneedle application. The results indicate that therapeutic 412 
Fig. 8 
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levels of lidocaine could be reached within 0.15 hours or 9 minutes post application MN, in 413 
comparison to no pre-treatment requiring 40 minutes (Fig. 8c, 8d). The reason for this short lag time 414 
is due to lidocaine microparticles traveling at a shorter path length to the deep dermis layer. The 415 
stratum corneum layer has been bypassed by artificial microneedle cavities. Microneedle assisted 416 
cumulative release study with respect to lidocaine formulations has not been performed ex vivo to 417 
date. However, in vivo release studies have been performed using non degrading polymeric 418 
microneedle array coating of lidocaine alone, sustained approximately 15 minutes of delivery thus 419 
proven successful for rapid emergency anaesthesia (Zhang et al., 2012). In vivo release studies 420 
with ex vivo cumulative release studies are completely incomparable due to obvious differences in 421 
experimental procedures and removal of active drug for characterisation. The lidocaine NaCMC/gel 422 
1:1.6 ratio (Fig. 8a) hydrogel crosses the therapeutic level at significantly slower time duration, 423 
greater than 30 minutes in lidocaine NaCMC/gel 1:2.66 ratio in comparison of microneedle and LFS 424 
treatment. This is due to the fact that microneedles and ultrasound are involved in either cavity 425 
engulfing of larger sized hydrogel microparticles.  426 
 427 
3.10 Microneedle and ultrasound (dual) pre-treatment of lidocaine NaCMC/gel ratio 1:2.66 hydrogel 428 
Both pre-treatments (dual) were combined and studied for further permeation enhancement in 429 
comparison to microneedle or LFS pre-treatment only. Lidocaine NaCMC/gel 1:2.66 hydrogel in 430 
which combining a 10 minute application of 18W LFS after a 5 minute application of microneedles 431 
demonstrated an initial faster permeation by 23 fold with an average 4.8 fold increase over 30 432 
minutes of application when compared with separate device treatments and passive diffusion (Fig. 433 
8d). Therapeutic levels of lidocaine could theoretically be reached after 7 minutes post application in 434 
terms of reaching the deep dermis layer of skin as the target. A general increase in permeation 435 
throughout the period of experimentation can be noticed rather than post 2 hours as seen with LFS 436 
pre-treatment only, this could be due to efficiency of LFS pre-treatment is further enhanced on 437 
porous skin sample formed via the microneedle patch. 438 
 439 
3.11 Dual pre-treatment of lidocaine NaCMC/gel 1:2.66 hydrogel via rotary evaporation method 440 
Lidocaine NaCMC/gel 1:2.66 hydrogel with the rotary evaporation method as described earlier, 441 
favoured an additional time of nearly 0.9 hour or fifty minutes after the application of 18W LFS at 10 442 
minutes (P < 0.04) to reach minimum therapeutic level in conjunction to a two fold average increase 443 
in permeation after 1 hour, compared with the same formulation without rotary evaporation method 444 
(Fig. 8d, 8e). This was the likelihood of higher heating temperatures compromising the 445 
glutaraldehyde fixation and thus resulting in larger microparticle as previously reported. Higher 446 
heating temperatures were required in the large volume removal of n-hexane and paraffin oil 447 
mixture by solvent evaporation. A 5 minute application of the microneedle array led to an initial 448 
increase by 2.8 fold and subsequently an average 3.4 fold increase was observed with respect to 449 
the deep dermis layer skin target. Combining the two pre-treatments resulted in an initial permeation 450 
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increase by 3.8 fold followed by an average increase by 4.1 fold in comparison to passive diffusion 451 
only (Fig. 8d, 8e). Therapeutic levels of lidocaine were reduced from just over 2 hours to less than 1 452 
hour on average.  453 
3.12 Mass transfer of lidocaine from NaCMC/gel 1:2.66 hydrogel 454 
The percentage of lidocaine remaining inside ex vivo skin was determined by the subtraction of the 455 
mass of lidocaine initially encapsulated during formulated preparation (125000 µg) by the 456 
cumulative amount detected in DI water from controlled release studies. The purpose of using 457 
controlled release studies is to determine the amount of lidocaine contained in the vehicle as mass 458 
balance before the subtraction of the mass of lidocaine in the receptor in which the DI water in the 459 
receptor is the deep dermis. All mass balances were carried out in µg and converted from 460 
cumulative concentration units of µg/ml before the percentage of lidocaine remaining inside the skin 461 
was determined (Fig. 9). Overall the mass transfer of lidocaine with respect to all treatment 462 
applications appeared to outline a gradual, slow process of diffusing through the full thickness 463 
appendage. However there is a fairly substantial decline in the percentage of lidocaine remaining in 464 
the skin when microneedle and ultrasound treatment (LFS) method was applied. This can be 465 
interpreted as diffusion of lidocaine molecules through skin cells and layers before clearance into 466 
the blood stream. The lowest percentage of lidocaine remaining in the skin is 99.7 % after a time of 467 
3 hours (Fig. 9).  468 
  469 
4 Conclusions 470 
This study aimed to use low frequency sonophoresis and microneedles as a pre-treatment to skin in 471 
order to enhance permeation of lidocaine encapsulated in a formulation. A significantly more 472 
microparticle stability was found with lower gelatine ratios (1:1.60); however all formulations were 473 
sufficiently stable (zeta potential: ≥ -30mV). Our diffusion experiments revealed a small increase in 474 
diffusional permeation when low frequency sonophoresis was used in combination with a 475 
microneedle array pre-treated skin. However, rotary evaporation during the final polymeric drug 476 
formulation stage caused significant reductions in lidocaine permeation levels. Nota bene that the 477 
main purpose for utilising rotary evaporation was for reduced time in removal of a large volume of 478 
residual paraffin and n-hexane as the final operative method compared to vacuum oven drying (data 479 
not shown). Lidocaine NaCMC/gel 1:2.66 and lidocaine NaCMC/gel hydrogel 1:2.66 formulated by 480 
rotary evaporation showed a decreased time required to reach minimum therapeutic levels of 481 
lidocaine by 5.7 and 2 fold, respectively. Generally, lidocaine permeation was significantly increased 482 
with higher sonophoresis power and increasing exposure duration demonstrated a minor increase of 483 
the permeation rate for lidocaine NaCMC/gel hydrogel formulations. Also the microneedle 484 
application time duration of 5 minutes resulted in a highly favourable increase in lidocaine 485 
permeation. Furthermore, combining microneedle and low frequency sonophoresis pre-treatments 486 
allowed for the time to reach minimum therapeutic lidocaine levels to be significantly reduced, For 487 
Fig. 9 
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example, in the case of lidocaine NaCMC/gel, 1:2.66 hydrogel therapeutic thresholds of lidocaine 488 
were reached within 7 minutes of application. The mass transfer effects in which the percentage of 489 
lidocaine remained in the full skin depicted the gradual movement of drug in targeting pain receptors 490 
below the SC layer. The lidocaine NaCMC/gel 1:2.66 hydrogel treated by microneedles and LFS 491 
shows a greater mass transfer profile. The US and MN treated lidocaine NaCMC/gel 1:2.66 has a 492 
0.18 % mass transfer of lidocaine through skin within 2 hours compared with 0.01 % mass transfer 493 
of lidocaine through skin. Therefore, this method is promising and could be of medical use as a 494 
painless, easy to administer technique for drug delivery overcoming the time constraints associated 495 
with delivery of lidocaine. Lidocaine NaCMC/gel 1:2.66 hydrogel is likely to be the most desirable 496 
drug formulation candidate for further developmental studies reaching potentially important pre-497 
clinical and final post clinical stage developments. In order to develop a less polydisperse but low 498 
micron scale lidocaine hydrogel formulation requires a longer time frame and added investment. 499 
The resources and materials in developing a lidocaine NaCMC/gel 1:2.66 hydrogel without rotary 500 
evaporation is economical on a batch scale at present. Lidocaine. NaCMC/gel 1:2.33 formulation 501 
with defined morphological appearance is able to remain on the surface of the skin for longer 502 
durations compared with a lidocaine solution of the same mass loading. 503 
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 696 
  697 
Sample 
ID 
NaCMC 
(% w/v) 
Gelatine 
(c % w/w) 
Lidocaine 
(% w/w) 
NaCMC:Gelatine 
ratio Drier Type 
Mean Particle  
Diameter ± S.D. 
(μm)  
Particle 
Diameter range 
(μm) 
F1 1.2 2.0 2.4 1:1.6 Vacuum 5.89 ± 0.0026 1 - 13 
F2 1.2 2.4 2.4 1:2.00 Vacuum 6.04 ± 0.0027 1 - 14 
F3 1.2 2.8 2.4 1:2.33 Vacuum 6.81 ± 0.0029 2 - 17 
F4 1.2 3.2 2.4 1:2.67 Vacuum 7.42 ± 0.0029 3 - 17 
F5 1.2 3.2 2.4 1:2.67 Rotary 14.60 ± 0.0067 4 - 31 
 
Table 1  
Lidocaine NaCMC/gel hydrogel mass ratio with particle size values 
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 700 
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Fig. 1. Micrograph of a. lidocaine NaCMC;gel 1:2.33 hydrogel showing distinctly formed microparticles. 
b. lidocaine NaCMC:gel 1:2.66 hydrogel showing larger and slightly more agglomerated microparticles.  
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Fig. 2.  Particle size distribution of Lidocaine NaCMC/gel hydrogels 
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  711 
Fig. 3.  Lidocaine NaCMC/GEL 1:1.6 to 1:2.66 (F1 to F4) and lidocaine 
NaCMC/GEL1:2.66 by rotary evap prep. (F5)  for zeta potential 
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Fig. 4. Lidocaine 2.44 % w/w NaCMC/GEL ratio pseudoplasticity  
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 727 
 728 
Fig. 5  Lidocaine NaCMC/gel 1:2.33 comparison with Newtonian lidocaine solution according to a. droplet heights b. 729 
spreading radii c. apparent contact angles. The results suggest that the spreading of lidocaine NaCMC/gel 1:2.33 on 730 
the skin surface is much more predictable/controllable as compared to lidocaine solution.  731 
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Fig. 6. The controlled release of Lidocaine 2.44% w/w encapsulated a. NaCMC/GEL 1:1.6 (F1), NaCMC/GEL 1:2.0 
(F2), NaCMC/GEL 1:2.33 (F3) and NaCMC/GEL 1:2.66 (F4) b.  as a percentage into DI water medium from 
NaCMC/GEL 1:1.6 (F1), NaCMC/GEL 1:2.0 (F2), NaCMC/GEL 1:2.33 (F3) and NaCMC/GEL 1:2.66 (F4). The error 
bars in a) the standard deviation of mean represents the error. b) No error bars indicated 
a 
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 741 
 742 
Fig. 7 The microneedle insertion depth of skin sample using 1100 µm microneedles under thumb 743 
pressure. The histological studies shows that although the microneedles are 1100 µm, for the 744 
microneedle density in the array and force applied, they creates holes of approximately 400 µm. 745 
  746 
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Fig. 8. Cumulative lidocaine permeation from Lidocaine. a NaCMC/GEL 1:1.6 (F1), NaCMC/GEL 1:2.0 (F2), 
NaCMC/GEL 1:2.33 (F3),  NaCMC/GEL 1:2.66 (F4) and passive diffusion (PD) NaCMC/GEL 1:2.66 by rotor 
evaporation  prep stage (F5). b F4 PD and comparative pre-treatment with ultrasound at 15W and 18W for 5 and 
10 minutes respectively. c F4 adapting a microneedle (MN) patch for a 3 minute and 5 minute pre-treatment 
duration for Lidocaine NaCMC/GEL 1:2.66. d F4 adapting NaCMC/GEL 1:2.66 (F4 PD), NaCMC/GEL 1:2.66 (F4 
US, 18W 10min.), NaCMC/GEL 1:2.66 (F4 MN, 5 min.) and NaCMC/GEL 1:2.66  (F4 MN 5 min and US 18W 
10min). e NaCMC/GEL 1:2.66 (F5 PD), NaCMC/GEL 1:2.66 (F5 LFS, 18W 10min.), NaCMC/GEL 1:2.66 (F5 
MN, 5 min.) and NaCMC/GEL 1:2.66 (F5 MN 5 min, LFS, 18W 10min). 
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Fig. 9. Percentage of lidocaine contained in (F4) NaCMC/GEL 1:2.66 (    Passive Diffusion), (    microneedles, 3 min), 779 
(    microneedles, 5 min.), (  LFS 5 min 15W), (    LFS 10 min 18W), (     MN + LFS). (Error bars outline a 780 
random error range of 0.005 %)  781 
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